Broadwood Partners, L.P. Buys 22,189 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 22,189 shares of the firm’s stock in a transaction dated Monday, March 31st. The stock was purchased at an average cost of $17.46 per share, with a total value of $387,419.94. Following the acquisition, the insider now directly owns 12,455,264 shares in the company, valued at $217,468,909.44. This trade represents a 0.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, April 2nd, Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Thursday, March 27th, Broadwood Partners, L.P. bought 3,620 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was bought at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The shares were bought at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The stock was purchased at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was purchased at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The stock was acquired at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.50 per share, with a total value of $176,751.50.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $17.40 on Friday. The business has a fifty day simple moving average of $18.99 and a two-hundred day simple moving average of $24.87. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The company has a market capitalization of $858.26 million, a price-to-earnings ratio of -42.44 and a beta of 0.66.

Institutional Trading of STAAR Surgical

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after acquiring an additional 31,212 shares during the last quarter. HighTower Advisors LLC acquired a new position in STAAR Surgical in the 3rd quarter valued at $336,000. Polar Asset Management Partners Inc. increased its position in STAAR Surgical by 44.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock worth $6,271,000 after buying an additional 51,800 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of STAAR Surgical by 411.7% during the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after buying an additional 172,779 shares in the last quarter. Finally, Defender Capital LLC. boosted its position in shares of STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock valued at $17,041,000 after acquiring an additional 23,950 shares during the period. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on STAA. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus reduced their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. Finally, William Blair downgraded shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.